by ScienceDaily
For decades, Alzheimer’s disease research has focused heavily on the accumulation of beta-amyloid plaques in the brain. However, growing evidence suggests that the disease is not only a consequence of toxic protein buildup but also of the brain’s declining ability to respond to it.
A new study led by José Vicente Sánchez Mut of the Institute for Neurosciences (IN-CSIC-UMH) in Spain and Johannes Gräff of EPFL in Switzerland highlights a promising approach: restoring the protective functions of microglia, the brain’s resident immune cells.
The researchers investigated OLE, a molecule derived from the PM20D1 gene, and found that it could shift microglia into a more protective state. Rather than simply reducing beta-amyloid levels, OLE appeared to help microglia migrate toward plaques and surround them, creating a barrier that limited their harmful interaction with nearby neurons.
According to Sánchez Mut, “one of the most significant findings is that we have identified a molecule capable of restoring microglia’s protective function.” The study suggests that the progressive impairment of these cells in Alzheimer’s disease may not be irreversible, opening new avenues for both therapeutic development and basic research.
The findings were supported across multiple experimental systems. In genetically modified C. elegans models that produce beta-amyloid, OLE reduced protein aggregation and improved movement. In mouse models of Alzheimer’s disease, three months of treatment resulted in improved memory performance and fewer beta-amyloid plaques. Single-cell analyses further revealed that microglia were the cell type most strongly affected by the treatment, activating pathways associated with beta-amyloid clearance and regaining their ability to contain plaque-related damage.
Importantly, the study also reported beneficial effects in cell culture models, where OLE-treated microglia demonstrated enhanced plaque-clearing behavior and neuronal cultures showed improved survival under Alzheimer’s-like conditions.
While these findings remain preclinical, they reinforce the growing importance of microglia as a therapeutic target in Alzheimer’s disease. Rather than focusing exclusively on the plaques themselves, future interventions may seek to strengthen the brain’s own defense mechanisms. The identification of OLE and its effects on microglial function provides an intriguing example of how reactivating endogenous protective pathways could contribute to the next generation of Alzheimer’s therapies.
Potential for Future Alzheimer’s Therapies
The findings are covered by two European patents, including one owned by the CSIC. The researchers say this strengthens the translational potential of the work and supports future efforts to develop therapeutic applications based on the discovery.
The study received funding from the Dementia Research Switzerland — Synapsis Foundation (Switzerland), the Pasqual Maragall Researchers Programme (PMRP) of the Pasqual Maragall Foundation, the Spanish Ministry of Science, Innovation and Universities, the Severo Ochoa Centres of Excellence programme of the State Research Agency (AEI), the Prometeo program of the Generalitat Valenciana, the European Regional Development Fund (ERDF), and the CSIC Interdisciplinary Thematic Platform PTI+ NEURO-AGING. Additional support came from the Swiss National Science Foundation, the École Polytechnique Fédérale de Lausanne (EPFL), the European Research Council (ERC), the National Research Foundation of Korea (NRF), and the European Social Fund (ESF+).
Research article:
Pozzi-Ruiz, V., Giner de Gracia, A., Glauser, L. et al. The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease. Cell Death Dis 17, 561 (2026). https://doi.org/10.1038/s41419-026-08791-1
Lambda Biologics’ Brain Organoid Platforms
Midbrain Organoid | Cerebral Organoid | Brain Disease Models | Parkinson Disease Model
